^
    Back
    Association details:
    Biomarker:EML4-ALK G1202R
    Cancer:Non Small Cell Lung Cancer
    Drug Class:ALK inhibitor +
    STAT3 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Cell Signal
    Title:

    EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling

    Published date:
    04/01/2022
    Excerpt:
    ...the combination of ALK and STAT3 inhibitors restored the sensitivity of EML4-ALK G1202R mutant cells to ceritinib. In conclusion, these data indicate that the EML4-ALK G1202R mutation mediates the EMT phenotype by activating the STAT3/Slug signaling pathway, resulting in resistance to ceritinib, and that the combination of STAT3 and ALK inhibitors may overcome ALK mutation-driven drug resistance in the clinic.
    DOI:
    10.1016/j.cellsig.2022.110264